Role Of Brain Serotonin In Animal Models Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$175,550.00
Summary
There is increasing evidence that deficiencies in the release of a brain chemical called serotonin play an important role in the development of schizophrenia. Post-mortem studies have shown changes in the levels of 'receptors' (keyholes for messenger chemicals in the brain) for serotonin in schizophrenia. In addition, in the treatment of schizophrenia, the more recently introduced 'atypical' antipsychotic drugs are superior to the more traditional 'typical' antipsychotics in terms of efficacy an ....There is increasing evidence that deficiencies in the release of a brain chemical called serotonin play an important role in the development of schizophrenia. Post-mortem studies have shown changes in the levels of 'receptors' (keyholes for messenger chemicals in the brain) for serotonin in schizophrenia. In addition, in the treatment of schizophrenia, the more recently introduced 'atypical' antipsychotic drugs are superior to the more traditional 'typical' antipsychotics in terms of efficacy and side-effect profile. Typical antipsychotic drugs act mainly through blockade of receptors for a brain chemical called dopamine. Atypical drugs appear to have additional actions, in particular blocking the effect of serotonin in the brain. This evidence is mostly circumstancial, relying to a large extent on biochemical analysis of brain regions and 'receptors' on which antipsychotics MAY act. It is currently unclear exactly how and where in the brain changes in serotonin activity influence behavioural processes causing schizophrenia. It is also unclear how and where typical and atypical antipsychotic drugs interact with the role of serotonin in schizophrenia. In this project we intend to inactivate specific parts of the serotonin system of otherwise intact, freely moving rats. Using behavioural observation methods relevant for schizophrenia, we will analyze if and how these interventions influence the behaviour of these rats. The results can have important implications for our fundamental understanding of the involvement of serotonin in the brain in schizophrenia.Read moreRead less
A Multi-national Trial To Predict Treatment Response In Subtypes Of Depression
Funder
National Health and Medical Research Council
Funding Amount
$387,489.00
Summary
Treatment of MDD using trial and error can have serious consequences. It can prolong the patient’s suffering (depression is associated with substantial morbidity, and mortality), prolong their absence from work and other productive activity and increase the burden on their family-carers. This multi-national study will collect genetics, brain function and behavioural data from a large number of participants, allowing for sensitive predictors of response to be determined.